Background:Cancer is one of the leading causes of death globally,but its burden is not uniform.GLOBOCAN 2020 has newly updated the estimates of cancer burden.This study summarizes the most recent changing profiles of ...Background:Cancer is one of the leading causes of death globally,but its burden is not uniform.GLOBOCAN 2020 has newly updated the estimates of cancer burden.This study summarizes the most recent changing profiles of cancer burden worldwide and in China and compares the cancer data of China with those of other regions.Methods:We conducted a descriptive secondary analysis of the GLOBOCAN 2020 data.To depict the changing global profile of the leading cancer types in 2020 compared with 2018,we extracted the numbers of cases and deaths in 2018 from GLOBOCAN 2018.We also obtained cancer incidence and mortality from the 2015 National Cancer Registry Report in China when sorting the leading cancer types by new cases and deaths.For the leading cancer types according to sex in China,we summarized the estimated numbers of incidence and mortality,and calculated China’s percentage of the global new cases and deaths.Results:Breast cancer displaced lung cancer to become the most leading diagnosed cancer worldwide in 2020.Lung,liver,stomach,breast,and colon cancers were the top five leading causes of cancer-related death,among which liver cancer changed from the third-highest cancer mortality in 2018 to the second-highest in 2020.China accounted for 24%of newly diagnosed cases and 30%of the cancer-related deaths worldwide in 2020.Among the 185 countries included in the database,China’s age-standardized incidence rate(204.8 per 100,000)ranked 65th and the age-standardized mortality rate(129.4 per 100,000)ranked 13th.The two rates were above the global average.Lung cancer remained the most common cancer type and the leading cause of cancer death in China.However,breast cancer became the most frequent cancer type among women if the incidence was stratified by sex.Incidences of colorectal cancer and breast cancer increased rapidly.The leading causes of cancer death varied minimally in ranking from 2015 to 2020 in China.Gastrointestinal cancers,including stomach,colorectal,liver,and esophageal cancers,contributed to a massive bu展开更多
Background:Cancer is one of the leading causes of death and a main economic burden in China.Investigating the differences in cancer patterns and control strategies between China and developed countries could provide r...Background:Cancer is one of the leading causes of death and a main economic burden in China.Investigating the differences in cancer patterns and control strategies between China and developed countries could provide reference for policy planning and contribute to improving cancer control measures.In this study,we reviewed the rates and trends of cancer incidence and mortality and disability-adjusted life year(DALY)burden in China,and compared them with those in the United States(US)and the United Kingdom(UK).Methods:Cancer incidence,mortality,and DALY data for China,US and UK were obtained fromtheGLOBOCAN2020 online database,Global Burden of Disease(GBD)2019 study,and Cancer Incidence in Five Continents plus database(CI5 plus).Trends of cancer incidence and mortality in China,US,and UK were analyzed using Joinpoint regression models to calculate annual percent changes(APCs)and identify the best-fitting joinpoints.Results:An estimated 4,568,754 newly diagnosed cancer cases and 3,002,899 cancer deaths occurred in China in 2020.Additionally,cancers resulted in 67,340,309 DALYs in China.Compared to the US and UK,China had lower cancer incidence but higher cancer mortality andDALY rates.Furthermore,the cancer spectrum of China was changing,with a rapid increase incidence and burden of lung,breast,colorectal,and prostate cancer in addition to a high incidence and heavy burden of liver,stomach,esophageal,and cervical cancer.Conclusions:The cancer spectrum of China is changing from a developing country to a developed country.Population aging and increase of unhealthy lifestyles would continue to increase the cancer burden of China.Therefore,the Chinese authorities should adjust the national cancer control program with reference to the practices of cancer control which have been well-established in the developed countries,and taking consideration of the diversity of cancer types by of different regions in China at the same time.展开更多
背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disabi...背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disability-adjusted life year,DALY)负担的比率及趋势,并与美国(United States,US)和英国(United Kingdom,UK)进行了比较。方法 本研究从GLOBOCAN 2020在线数据库、2019年全球疾病负担(global burden of disease,GBD)研究和五大洲癌症发病率plus数据库(Cancer Incidence in Five Continents plus database,CI5 plus)中获取中国、美国和英国的癌症发病率、死亡率和DALY数据。使用Joinpoint回归模型分析中国、美国和英国癌症发病率和死亡率的趋势,计算年度百分比变化(annual percent change,APC),并确定最佳拟合连接点。结果 2020年估算的中国新发癌症病例为4,568,754例,癌症死亡病例为3,002,899例。此外,在中国,癌症引起的DALY为67,340,309。与美国和英国相比,中国的癌症发病率更低,但癌症死亡率和DALY率更高。此外,中国的癌症谱正在发生变化,除了肝癌、胃癌、食管癌和宫颈癌的发病率高和负担沉重外,肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担正在迅速增长。结论 中国的癌症谱正在从发展中国家向发达国家转变。人口老龄化和不健康生活方式将继续增加中国的癌症负担。因此,中国应参考发达国家已建立的癌症防控策略,并结合中国不同地区癌症类型的多样性,调整国家癌症控制政策。展开更多
China's Mars probe,named Tianwen-1,including an orbiter and a landing rover,will be launched during the July-August 2020 Mars launch windows.Selected to be among the rover payloads is a Subsurface Penetrating Rada...China's Mars probe,named Tianwen-1,including an orbiter and a landing rover,will be launched during the July-August 2020 Mars launch windows.Selected to be among the rover payloads is a Subsurface Penetrating Radar module(RoSPR).The main scientific objective of the RoSPR is to characterize the thickness and sub-layer distribution of the Martian soil.The RoSPR consists of two channels.The low frequency channel of the RoSPR will penetrate the Martian soil to depths of 10 to 100 m with a resolution of a few meters.The higher frequency channel will penetrate to a depth of 3 to 10 m with a resolution of a few centimeters.This paper describes the design of the instrument and some results of field experiments.展开更多
The Chinese Pharmacopoeia 2020 edition was reviewed and approved by the National Medical Products Administration and the National Health Commission of the People’s Republic of China in July 2020.The current edition w...The Chinese Pharmacopoeia 2020 edition was reviewed and approved by the National Medical Products Administration and the National Health Commission of the People’s Republic of China in July 2020.The current edition was officially implemented on December 30,2020.The general chapters of the Chinese Pharmacopoeia discuss the general testing methods and guidelines,which are the common requirements and basis for the implementation of drug standards in the Chinese Pharmacopoeia.Owing to adherence to the principles of scientificity,versatility,operability,and sustainable development,there is an improvement in the general chapters of the 2020 edition over those of the previous editions.Further,the application of advanced and mature analytical techniques has expanded,the development of testing methods for exogenous pollutants in traditional Chinese medicines has been strengthened,and technical requirements are now better harmonized with international standards.The updated edition provides technical and methodological support to ensure safety,effectiveness,and control of pharmaceuticals in China and will play an important and active role in encouraging the application of advanced technologies,improving the quality control of medicines,and strengthening the means of drug regulation in China.This review provides a comprehensive introduction of the main features of and changes to the general chapters in the Chinese Pharmacopoeia 2020 edition and aims to provide reference for its correct understanding and accurate implementation.展开更多
文摘Background:Cancer is one of the leading causes of death globally,but its burden is not uniform.GLOBOCAN 2020 has newly updated the estimates of cancer burden.This study summarizes the most recent changing profiles of cancer burden worldwide and in China and compares the cancer data of China with those of other regions.Methods:We conducted a descriptive secondary analysis of the GLOBOCAN 2020 data.To depict the changing global profile of the leading cancer types in 2020 compared with 2018,we extracted the numbers of cases and deaths in 2018 from GLOBOCAN 2018.We also obtained cancer incidence and mortality from the 2015 National Cancer Registry Report in China when sorting the leading cancer types by new cases and deaths.For the leading cancer types according to sex in China,we summarized the estimated numbers of incidence and mortality,and calculated China’s percentage of the global new cases and deaths.Results:Breast cancer displaced lung cancer to become the most leading diagnosed cancer worldwide in 2020.Lung,liver,stomach,breast,and colon cancers were the top five leading causes of cancer-related death,among which liver cancer changed from the third-highest cancer mortality in 2018 to the second-highest in 2020.China accounted for 24%of newly diagnosed cases and 30%of the cancer-related deaths worldwide in 2020.Among the 185 countries included in the database,China’s age-standardized incidence rate(204.8 per 100,000)ranked 65th and the age-standardized mortality rate(129.4 per 100,000)ranked 13th.The two rates were above the global average.Lung cancer remained the most common cancer type and the leading cause of cancer death in China.However,breast cancer became the most frequent cancer type among women if the incidence was stratified by sex.Incidences of colorectal cancer and breast cancer increased rapidly.The leading causes of cancer death varied minimally in ranking from 2015 to 2020 in China.Gastrointestinal cancers,including stomach,colorectal,liver,and esophageal cancers,contributed to a massive bu
文摘Background:Cancer is one of the leading causes of death and a main economic burden in China.Investigating the differences in cancer patterns and control strategies between China and developed countries could provide reference for policy planning and contribute to improving cancer control measures.In this study,we reviewed the rates and trends of cancer incidence and mortality and disability-adjusted life year(DALY)burden in China,and compared them with those in the United States(US)and the United Kingdom(UK).Methods:Cancer incidence,mortality,and DALY data for China,US and UK were obtained fromtheGLOBOCAN2020 online database,Global Burden of Disease(GBD)2019 study,and Cancer Incidence in Five Continents plus database(CI5 plus).Trends of cancer incidence and mortality in China,US,and UK were analyzed using Joinpoint regression models to calculate annual percent changes(APCs)and identify the best-fitting joinpoints.Results:An estimated 4,568,754 newly diagnosed cancer cases and 3,002,899 cancer deaths occurred in China in 2020.Additionally,cancers resulted in 67,340,309 DALYs in China.Compared to the US and UK,China had lower cancer incidence but higher cancer mortality andDALY rates.Furthermore,the cancer spectrum of China was changing,with a rapid increase incidence and burden of lung,breast,colorectal,and prostate cancer in addition to a high incidence and heavy burden of liver,stomach,esophageal,and cervical cancer.Conclusions:The cancer spectrum of China is changing from a developing country to a developed country.Population aging and increase of unhealthy lifestyles would continue to increase the cancer burden of China.Therefore,the Chinese authorities should adjust the national cancer control program with reference to the practices of cancer control which have been well-established in the developed countries,and taking consideration of the diversity of cancer types by of different regions in China at the same time.
文摘背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disability-adjusted life year,DALY)负担的比率及趋势,并与美国(United States,US)和英国(United Kingdom,UK)进行了比较。方法 本研究从GLOBOCAN 2020在线数据库、2019年全球疾病负担(global burden of disease,GBD)研究和五大洲癌症发病率plus数据库(Cancer Incidence in Five Continents plus database,CI5 plus)中获取中国、美国和英国的癌症发病率、死亡率和DALY数据。使用Joinpoint回归模型分析中国、美国和英国癌症发病率和死亡率的趋势,计算年度百分比变化(annual percent change,APC),并确定最佳拟合连接点。结果 2020年估算的中国新发癌症病例为4,568,754例,癌症死亡病例为3,002,899例。此外,在中国,癌症引起的DALY为67,340,309。与美国和英国相比,中国的癌症发病率更低,但癌症死亡率和DALY率更高。此外,中国的癌症谱正在发生变化,除了肝癌、胃癌、食管癌和宫颈癌的发病率高和负担沉重外,肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担正在迅速增长。结论 中国的癌症谱正在从发展中国家向发达国家转变。人口老龄化和不健康生活方式将继续增加中国的癌症负担。因此,中国应参考发达国家已建立的癌症防控策略,并结合中国不同地区癌症类型的多样性,调整国家癌症控制政策。
基金support from the China National Space Administration.
文摘China's Mars probe,named Tianwen-1,including an orbiter and a landing rover,will be launched during the July-August 2020 Mars launch windows.Selected to be among the rover payloads is a Subsurface Penetrating Radar module(RoSPR).The main scientific objective of the RoSPR is to characterize the thickness and sub-layer distribution of the Martian soil.The RoSPR consists of two channels.The low frequency channel of the RoSPR will penetrate the Martian soil to depths of 10 to 100 m with a resolution of a few meters.The higher frequency channel will penetrate to a depth of 3 to 10 m with a resolution of a few centimeters.This paper describes the design of the instrument and some results of field experiments.
基金financial support from the Chinese Pharmacopoeia Commission Drug Standard Promoting Funds and Comprehensive Reform of the Chinese Drug and Medical Device Review and Approval System Funds(2015e2020)。
文摘The Chinese Pharmacopoeia 2020 edition was reviewed and approved by the National Medical Products Administration and the National Health Commission of the People’s Republic of China in July 2020.The current edition was officially implemented on December 30,2020.The general chapters of the Chinese Pharmacopoeia discuss the general testing methods and guidelines,which are the common requirements and basis for the implementation of drug standards in the Chinese Pharmacopoeia.Owing to adherence to the principles of scientificity,versatility,operability,and sustainable development,there is an improvement in the general chapters of the 2020 edition over those of the previous editions.Further,the application of advanced and mature analytical techniques has expanded,the development of testing methods for exogenous pollutants in traditional Chinese medicines has been strengthened,and technical requirements are now better harmonized with international standards.The updated edition provides technical and methodological support to ensure safety,effectiveness,and control of pharmaceuticals in China and will play an important and active role in encouraging the application of advanced technologies,improving the quality control of medicines,and strengthening the means of drug regulation in China.This review provides a comprehensive introduction of the main features of and changes to the general chapters in the Chinese Pharmacopoeia 2020 edition and aims to provide reference for its correct understanding and accurate implementation.
